Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORIC-944 + darolutamide
- Development stage
- Phase 3
- Lead developer
- ORIC Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of **ORIC-944**, a potent and selective allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit, and **darolutamide**, an androgen receptor inhibitor marketed as Nubeqa. This combination is under investigation for the treatment of metastatic castration-resistant prostate cancer (mCRPC), particularly for patients previously treated with androgen receptor pathway inhibitors and up to one prior chemotherapy. Early clinical trials demonstrate substantial clinical activity (high PSA50 and PSA90 response rates) and a favorable safety profile, predominantly mild to moderate gastrointestinal side effects.[1][2][3][4][5]
- Other names
- ORIC-944 + Nubeqa
02
Targets
AR (Adrenergic receptors)EED (Embryonic ectoderm development protein)
Beyond the preview
Go deeper on ORIC-944 + darolutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORIC-944 + darolutamide.